Alto Neuroscience

Alto Neuroscience Dividend Coverage

Dividend Coverage Ratio of Alto Neuroscience (ANRO) as of Nov 21, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Alto Neuroscience is 2026 - . Dividend Coverage Ratio of Alto Neuroscience was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alto Neuroscience Stock analysis

What does Alto Neuroscience do? Alto Neuroscience Inc develops personalized psychiatric treatments using its Precision Psychiatry Platform, which analyzes neurocognitive assessments, electroencephalography, and wearable device data to identify brain-based biomarkers. The company's pipeline includes five clinical-stage assets: ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, targeting depressive disorder and schizophrenia based on biomarker identification. These assets are designed for patients more likely to respond to specific treatments, aiming to improve efficacy in mental health care. The company focuses on developing novel drug candidates for depression, PTSD, and other mental health conditions through its data-driven approach. Alto Neuroscience generates revenue primarily through partnerships with pharmaceutical companies that license its Precision Psychiatry Platform for biomarker discovery. These partnerships enable pharmaceutical firms to identify patient subgroups more likely to respond to their drug candidates, reducing clinical trial failure rates. The company's clinical-stage assets are developed internally, with potential future revenue from drug sales upon regulatory approval. The target customers for its platform are pharmaceutical companies seeking to optimize their mental health drug development pipelines. The company serves the mental health treatment segment by providing data-driven solutions to improve psychiatric care. Its primary focus is on depression, schizophrenia, PTSD, and other mental health conditions, using biomarker identification to tailor treatments. The Precision Psychiatry Platform is the core product, applied across multiple therapeutic areas to identify patient response patterns. Alto Neuroscience's approach targets the clinical development phase, where pharmaceutical companies need validated biomarkers to advance drug candidates. Alto Neuroscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alto Neuroscience stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Alto Neuroscience since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Alto Neuroscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Alto Neuroscience

All Key Metrics — Alto Neuroscience